DOES A LOSS OF FUNCTION POLYMORPHISM OF CYP2C19 MODULATE THE INTERACTION BETWEEN CLOPIDOGREL AND PROTON PUMP INHIBITORS? RESULTS OF A PARELLEL CROSSOVER TRIAL  by Nadipalli, Srinivas et al.
E1201
JACC April 5, 2011
Volume 57, Issue 14
  QUALITY OF CARE AND OUTCOMES ASSESSMENT 
DOES A LOSS OF FUNCTION POLYMORPHISM OF CYP2C19 MODULATE THE INTERACTION BETWEEN 
CLOPIDOGREL AND PROTON PUMP INHIBITORS? RESULTS OF A PARELLEL CROSSOVER TRIAL
ACC Poster Contributions
Ernest N. Morial Convention Center, Hall F
Sunday, April 03, 2011, 3:30 p.m.-4:45 p.m.
Session Title: Genetics and Outcomes
Abstract Category: 48. Genetics and Clinical Outcomes
Session-Poster Board Number: 1067-160
Authors: Srinivas Nadipalli, Sashidar Guthikonda, Timothy R. DelaO, Ali J. Marian, Federico Monzon, Ping Wang, Neal S. Kleiman, The Methodist 
Hospital Research Institute, Houston, TX, The Methodist DeBakey Heart and Vascular Center, Houston, TX
Background:  Omeprazole inhibits CYP 2C19 and may limit metabolic activation of clopidogrel. We wondered whether this effect would be most 
pronounced in individuals with 2C19 loss of function (LOF) mutations.
Methods:  We screened 102 healthy volunteers for *1 and *2 alleles of the CYP2C19 gene and performed a single blind parallel crossover 
study with 32 matched (age, BMI, sex, race) subjects with *1*1(n=16, wild type, WT) and *2*2 or *1*2 (n=16, LOF) genotypes. Subjects received 
clopidogrel 75 mg daily for 1 week, followed by 1 week of drug washout and then clopidogrel 75 mg and omeprazole 20 mg daily for 1 week. Blood 
samples were drawn at baseline and at the end of first and third weeks for light transmission aggregometry (LTA) (5 and 20 μM ADP) and VASP 
phosphorylation, expressed as platelet reactivity index (PRI).
Results:  After clopidogrel, mean LTA was lower in WT while PRI was higher compared with LOF genotype subjects (25.1±13.1 v 33.3±13.1 and 
36.4±13.0 v 49.8±14.3 for 5 and 20 μM ADP, as was PRI (36.0 ±25.4 v 52.5 ±22.3). The addition of omeprazole increased LTA and PRI in both 
groups, but this increase was greater in subjects with LOF mutations (Table).
Conclusion: Omeprazole administration in subjects taking clopidogrel decreased platelet inhibition, assessed by LTA and VASP in all subjects. 
However in subjects with LOF alleles, platelet inhibition is further reduced, probably due lower CYP2C19 “reserve”. 
Post Clopidogrel Inhibition Post Omeprazole Inhibition
WT LOF Δ Delta p-value WT LOF Δ Delta p-value
5ADP 49.3±15.3 46.8±12.8 5.9±21.8 0.115 46.8±12.8 31.0±11.2 12.8±11.4 0.0176
20ADP 43.7±11.9 32.8±15.8 10.0±20.5 0.0135 32.8±15.8 19.5±8.8 11.8±12.6 0.0626
VASP/PRI 36±25.4 52.5±22.3 13.4±42.3 0.131 43.8±17.2 69.3±14.7 25.4±23.2 0.0114
